Dr Steven van Helden

Steven van Helden (PhD) was trained as a computational chemist. He has worked in various roles in pharmaceutical industry since 1992. In 2003 he became head of Organon’s HTS group and following the closure of the research site in 2011 he developed a business plan to continue the screening activities in a new company. This led to formation of the Pivot Park Screening Centre in 2012 where he is now Chief Technology Officer.